Results 151 to 160 of about 18,251 (231)

Teriparatide in Two Patients With Mucopolysaccharidosis Type IVB. [PDF]

JIMD Rep
Wijnen M, van Velsen EFS, Milhous JG, Oussoren E, van der Eerden BCJ, Wagenmakers MAEM.   +5 more
europepmc   +1 more source

Correction: Time-dependent improvement of quality of life with teriparatide or alendronate therapy: a JOINT-05 sub-analysis. [PDF]

J Bone Miner Metab
Mori S, Tanaka S, Kuroda T, Hagino H, Soen S.   +4 more
europepmc   +1 more source

A systematic review of combination treatment strategies for osteoporosis. [PDF]

JBMR Plus
Nayak S, Greenspan SL.
europepmc   +1 more source

Knowledge and Adherence to Alendronate Administration Among Postmenopausal Osteoporosis Patients: A Cross-Sectional Study From a Tertiary Care Facility in Colombo South. [PDF]

Cureus
Prashanthan J, Prashanthan A, Meegoda Widanege N, Garusinghe C.   +3 more
europepmc   +1 more source

Bisphosphonate-related ocular adverse events: a pharmacovigilance study based on the FAERS database. [PDF]

Endocr Connect
Cui Y, Song Z, Wang X.
europepmc   +1 more source

Efficacy of denosumab versus alendronate for aromatase inhibitor-associated osteoporosis in postmenopausal breast cancer patients: a retrospective analysis. [PDF]

BMC Musculoskelet Disord
Zhang Y, Cui W, Hou L.
europepmc   +1 more source

Cost-Effectiveness of Fracture Prevention in Postmenopausal Women With Early Breast Cancer in China. [PDF]

J Cachexia Sarcopenia Muscle
Liu JY, Lin XH, Chen YH, Wang L, Liu T, Zhang Y, Mori T, Moriwaki K, You RX.   +8 more
europepmc   +1 more source

Drugs against osteoporosis in perimenopausal and postmenopausal women. [PDF]

Front Med (Lausanne)
Lv H, Zhang Y, Li J, Jia Q, Yu Y, Tang H, Chen W, Yang Y, Jiang Q, Chen J.   +9 more
europepmc   +1 more source

Cost-effectiveness analysis of low bone mass prevention in Chinese older men with excessive alcohol consumption: a modelling study. [PDF]

BMJ Open
Lin X, Liu J, Wang L, Liu T, Zhang Y, Moriwaki K, You R.   +6 more
europepmc   +1 more source

Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004-2024). [PDF]

PLoS One
Qin N, Gan Y, Ouyang J, Qin J, Tang Y, Wu H, Wei S, Wang H, Huang J.   +8 more
europepmc   +1 more source